To recognize outstanding contributions and excellence to the field of clinical nurse specialists, the Clinical Nurse Specialist Institute (CNSI) selected 38 nurses to its inaugural class of fellows, including three ONS members Marilyn Chrisman, MS, APRN, GCNS-BC, Patricia Geddie, PhD, CNS, AOCNSA, and Tina Mason, MSN, ARNP, AOCNA, AOCNSA. They will be among the first fellows to use the FCNS credential in practice.

As a continuation of the National Cancer Moonshot legacy, the Biden Cancer Initiative (BCI) announced its inaugural roster of FIERCE Award recipients, naming 10 transformative healthcare professionals and institutions who have driven change and positively impacted the lives of their patients with cancer. For her work as an oncology nurse navigator and her accomplishments in patient navigation, ONS member Cynthia Cantril, RN, OCN^®, CBCN^®, MPH, was named one of the BCI’s FIERCE Award recipients at the Biden Cancer Summit Welcome Reception in Washington, DC, on September 20, 2018.

As the U.S. government’s arm of patient-centered research, the Patient-Centered Outcomes Research institute (PCORI) is driving new initiatives and opportunities focused on unlocking novel treatment methods and cutting-edge interventions to better care for patients. On September 24, 2018, PCORI announced its new Board of Governors, naming ONS member Christopher Friese, PhD, RN, AOCN®, FAAN, as the agency’s first nursing research representative to hold a seat on the board.

Through contributions in the field, oncology nurses are driving the quality of cancer care forward, improving patient outcomes and enhancing quality of life and access to care. Whether they’re changing practice through innovation, research, excellence, or leadership, ONS members are making a big difference in practices across the country—and several have recently been recognized for their achievements in oncology nursing.

Even 10 years after diagnosis and without recurrence, cancer survivors have a higher opioid prescription rate than healthy controls, according to the results of a study published in Cancer.

Cancer treatment options continue to multiply as 2017 continues, with the U.S. Food and Drug Administration (FDA) granting multiple new drug approvals and broadening indications for others. Oncology clinicians and nurses are challenged with staying abreast of treatment option expansions and navigating the dynamic field of cancer treatment to effectively navigate their patients through the treatment trajectory, educating on vital points relative to treatment, minimizing morbidity and mortality, and optimizing quality of life. Following is an overview of the latest approvals for the second quarter of 2017.

Researchers have discovered a protein that may lead to a new way to prevent resistance and improve outcomes for patients whose cancers have a BRCA2 mutation. The findings were reported in Molecular Cell.

Researchers have found a new feature of cancer stem cells that may be used with existing cancer treatments to help prevent cancer recurrence. The study was reported in Cell Chemical Biology.

Beginning in January 2018, oncology nurses will see changes to the way their patients’ cancers are staged with the American Joint Committee on Cancer (AJCC) system. According to a presentation at the National Comprehensive Cancer Network annual conference in March 2017, when the AJCC 8th Edition Cancer Staging System takes effect on January 1, 2018, more cases may be classified as stage I, especially for patients with breast cancer.

Regina Cunningham, PhD, RN, NEABC, FAAN, has been appointed chief executive officer (CEO) of the Hospital of the University of Pennsylvania (HUP) in Philadelphia. Cunningham is the first nurse, oncology-specific or otherwise, to hold the position since the institution’s inception in 1874. She begins her tenure as CEO for HUP in April 2017.